Marie Châlons-Cottavoz

Title: Marie Châlons-Cottavoz: Innovator in Monoclonal Antibodies

Introduction

Marie Châlons-Cottavoz is a prominent inventor based in Lyons, France. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of two patents to her name, her work is paving the way for advancements in therapeutic and diagnostic methods.

Latest Patents

Her latest patents focus on humanized, mouse, or chimeric anti-CD47 monoclonal antibodies. These antibodies are designed to bind to human glycosylated and deglycosylated CD47 with an optimized Koff value. They disrupt the human CD47-SIRPα interaction, which is crucial for various therapeutic, preventive, or diagnostic applications. The invention encompasses isolated antibodies, derivatives, and fragments, as well as pharmaceutical formulations that include these monoclonal antibodies. Additionally, the patents provide amino acid and nucleotide sequences of the antibodies, further enhancing their utility in medical research.

Career Highlights

Marie Châlons-Cottavoz is currently associated with Forty Seven, Inc., where she continues to innovate in the field of monoclonal antibodies. Her work is instrumental in developing new treatments that could potentially improve patient outcomes in various diseases.

Collaborations

Some of her notable coworkers include Mehdi Lahmar and Klaus Heinrich Schwamborn. Their collaborative efforts contribute to the advancement of research and development in the biotechnology sector.

Conclusion

Marie Châlons-Cottavoz is a trailblazer in the field of monoclonal antibodies, with her innovative patents leading to significant advancements in therapeutic applications. Her contributions are vital to the ongoing evolution of biotechnology and medicine.